Dr. Anthony F. Nastase is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati. A former research scientist in medicinal chemistry and neuroscience drug development, Tony joins the patents and innovations practice with a focus on patent prosecution, diligence, and intellectual property. Areas of expertise include organic chemistry, small-molecule pharmaceuticals, biotechnology, and life sciences industries.
Prior to joining the firm, Tony was a postdoctoral research fellow in medicinal chemistry at the Vanderbilt Center for Neuroscience Drug Discovery. His doctoral research incorporated aspects of synthetic organic chemistry, structure-based drug design, pharmacology, and neuroscience directed toward the treatment of pain and opioid addiction. He also received recognition for his undergraduate research using computer-aided drug design to guide the treatment of Alzheimer’s disease. Tony has authored various peer-reviewed publications and is a co-inventor on one currently pending patent application.
Dr. Anthony F. Nastase is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati. A former research scientist in medicinal chemistry and neuroscience drug development, Tony joins the patents and innovations practice with a focus on patent prosecution, diligence, and intellectual property. Areas of expertise include organic chemistry, small-molecule pharmaceuticals, biotechnology, and life sciences industries.
Prior to joining the firm, Tony was a postdoctoral research fellow in medicinal chemistry at the Vanderbilt Center for Neuroscience Drug Discovery. His doctoral research incorporated aspects of synthetic organic chemistry, structure-based drug design, pharmacology, and neuroscience directed toward the treatment of pain and opioid addiction. He also received recognition for his undergraduate research using computer-aided drug design to guide the treatment of Alzheimer’s disease. Tony has authored various peer-reviewed publications and is a co-inventor on one currently pending patent application.
- Postdoctoral Fellowship, Vanderbilt University, 2019
- Ph.D., Medicinal Chemistry, University of Michigan, 2018
- B.S., Chemistry, Indiana University Purdue University – Indianapolis, 2013Recipient, 2013 Chancellor’s Award for Undergraduate Research
- U.S. Patent and Trademark Office
- Postdoctoral Fellowship, Vanderbilt University, 2019
- Ph.D., Medicinal Chemistry, University of Michigan, 2018
- B.S., Chemistry, Indiana University Purdue University – Indianapolis, 2013Recipient, 2013 Chancellor’s Award for Undergraduate Research
- U.S. Patent and Trademark Office
Select Publications:
- Co-author with J.P. Anand, A.M. Bender, D. Montgomery, N.W. Griggs, T.J. Fernandez, E.M. Jutkiewicz, J.R. Traynor, and H.I. Mosberg, “Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design,” 62(8) Journal of Medicinal Chemistry 4193-203, 2019
- Co-author with N.W. Griggs, J.P. Anand, T.J. Fernandez, A.A. Harland, T.J. Trask, E.M. Jutkiewicz, J.R. Traynor, and H.I. Mosberg, “Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain,” 9(7) ACS Chemical Neuroscience 1840-8, 2018
- Co-author with D.B. Boyd, “Simple Structure-Based Approach for Predicting the Activity of Inhibitors of beta-Secretase (BACE1) Associated with Alzheimer's Disease,” 52(12) Journal of Chemical Information and Modeling 3302-7, 2012
Select Publications:
- Co-author with J.P. Anand, A.M. Bender, D. Montgomery, N.W. Griggs, T.J. Fernandez, E.M. Jutkiewicz, J.R. Traynor, and H.I. Mosberg, “Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design,” 62(8) Journal of Medicinal Chemistry 4193-203, 2019
- Co-author with N.W. Griggs, J.P. Anand, T.J. Fernandez, A.A. Harland, T.J. Trask, E.M. Jutkiewicz, J.R. Traynor, and H.I. Mosberg, “Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain,” 9(7) ACS Chemical Neuroscience 1840-8, 2018
- Co-author with D.B. Boyd, “Simple Structure-Based Approach for Predicting the Activity of Inhibitors of beta-Secretase (BACE1) Associated with Alzheimer's Disease,” 52(12) Journal of Chemical Information and Modeling 3302-7, 2012
Gamma acquired a controlling stake in Mirus Bio in 2021 and has worked closely with the company to support its growth and scale-up, including the launch of flagship products VirusGEN® GMP and RevIT™ AAV Enhancer for large-scale therapeutic adeno-associated virus and lentivirus production. The transaction is expected to be completed in the third quarter of 2024, subject to U.S. regulatory approvals, as well as other customary closing conditions.
- Privacy Policy
- Terms of Use
- Accessibility